Saturday 17 October 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
22.04
0.66
−2.91%
Follow TNGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | — | — |
| (51.65%) | (37.23%) | (38.42%) | (21.34%) | ||
| (35.74%) | (28.41%) | (30.20%) | (18.86%) | ||
ROIC |
(1,015.30%) | (2,661.91%) | (629.60%) | (808.35%) | |
Return on Tangible Assets |
(65.83%) | (29.97%) | (27.90%) | (12.16%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(1.32) | (1.20) | (0.99) | (0.96) | |
Free Cash Flow |
(146.76) | (139.93) | (142.54) | (144.25) | |
Capital Expenditures |
(0.95) | (1.05) | (0.99) | (0.35) | |
| Other line items | |||||
Cash ROIC |
(46.85%) | (20.29%) | (18.48%) | (7.08%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
201.50% | 211.86% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
64.41% | 66.54% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
41.97% | 42.37% | 0.00% | 0.00% | |
Operating CF/Net income |
1.45 | 1.37 | 1.32 | 1.16 | |
Depreciation/Fixed assets |
(0.05) | (0.06) | (0.16) | (0.24) | |
Capex/Depreciation |
2.68 | 2.57 | 0.95 | 0.24 | |
Revenue per Share |
0.60 | 0.54 | 0.00 | 0.00 | |
Operating CF per Share |
(1.31) | (1.20) | (0.99) | (0.96) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.00 | 0.00 |
Columns are period end dates